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ABSTRACT 
Background 
Limited information exists regarding juvenile generalized pustular psoriasis (GPP). We 
aim to determine the clinical profile and outcome of Malaysians with juvenile GPP. 
Methods 
Review of hospital case notes on patients with juvenile GPP 
Results 
Twenty-seven patients with juvenile GPP were identified. Female: male =1.4:1. The 
median age at onset of GPP was 6.5 years. Ten patients had prior psoriasis with a median 
pre-pustular duration of 2.7 years. Onset of GPP was earlier in patients without prior 
psoriasis (5.1 years versus 12.0 years, p=0.002). Precipitating factors identified included 
stress, upper respiratory tract infection, systemic steroid use, vaccination and pregnancy. 
A positive family history of psoriasis and GPP was present in 6 and 1 patient(s) 
respectively.   
Twenty-one patients had acute, 5 annular and 1 localized variant of GPP. Arthritis was 
present in 22.2%. Fever, leukocytosis and transaminitis were mainly seen in patients with 
acute GPP at 80.9%, 72.2% and 11.1% respectively. Among 20 patients screened, 8 carry 
IL36RN variants and 1 has CARD14 mutation. IL36RN-positive patients have more 
severe disease characterized by early onset, low prevalence of prior PV, high prevalence 
of systemic inflammation and need for continuous long-term systemic therapy. Acitretin 
and cyclosporine were effective in aborting acute GPP in 100% of 16 and 66.7% of 6 
patients treated respectively. However, relapses were common. Only 3 out of the 17 
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patients whose initial acute GPP were controlled with systemic agents, were successfully 
weaned off treatment. 
Conclusions 
Juvenile GPP is a chronic recalcitrant disease. IL36RN-positive patients have more 
severe disease.  
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INTRODUCTION 
 
Psoriasis is a chronic inflammatory disease that affects about 2% of adults and 0.6% to 
1.4% of children.
1-2
 Onset during childhood was reported in 20-30% of affected adults.
1-2
 
Chronic plaque psoriasis (PV) is the most common phenotype of juvenile psoriasis 
whereas generalized pustular psoriasis (GPP) is most rare in children.
2-6
 Pustular psoriasis 
accounted for only 0.6- 6.7% of all childhood psoriasis.
2-4 
The first detailed clinical 
review of 104 GPP cases by Baker and Ryan, which included only 5 children, classified 
GPP into 4 clinical variants: acute GPP of von Zumbusch, sub-acute annular pustular 
psoriasis (APP), exanthematic and localized variant of GPP.
5 
 Although there were many 
subsequent case reports/series, few had more than 10 children with pustular psoriasis.
6-9
  
 
In a review of 13 children with GPP, Zelickson and Muller categorized juvenile and 
infantile pustular psoriasis into acute GPP, APP and a mixed acute GPP/APP variant.
6 
A 
more recent study of 18 childhood pustular psoriasis defined 4 variants; acute GPP, 
psoriasis vulgaris with pustulosis, APP and erythrodermic pustular psoriasis.
7
 Although 
distinct phenotypes of GPP were well documented
5-8
 there is little agreement on the 
classification of these clinical variants. The clinical course of these variants is largely 
unknown although pustular psoriasis may change from one clinical variant to another 
over time in the same patient.
6-9 
There is also limited information on the outcome of 
juvenile GPP especially in Asians although it is believed to be more benign than adult-
onset GPP. The objective of this study is to determine the clinical profile including 
demography, clinical variants, clinical course, treatment and long-term outcome of 
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juvenile GPP in our population. We also described a few patients in detail to highlight the 
sequential existence of different GPP variants in a patient and the challenges of treating 
recalcitrant juvenile GPP. 
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MATERIALS AND METHODS 
 
Study design and population 
 
This study was done by reviewing the medical records of dermatologist-confirmed GPP 
that developed before the age of 18 years. Only cases with clear documentation of at least 
one episode of widespread macroscopic sterile pustulosis that lasted more than 2 weeks 
were included. Data collection was done from November 2015 and updated till April 
2016. Data collected includes demographic characteristics (age, gender and ethnicity), 
personal and family history of psoriasis, clinical patterns of pustular psoriasis, 
precipitating factors, laboratory findings, biopsy results, genetic status, treatment and 
outcome of treatment. The genetic analysis of our patients with GPP had been previously 
described and reported.
10-12
 This study was approved by the Malaysian Ministry of Health 
Institutional Review Board and Medical Research Ethics Committee.  
 
Statistical analysis 
 
Descriptive statistics are presented as counts and percentages for categorical variables. 
Mean with standard deviation (SD) was used for normally distributed data while median 
with interquartile range (IQR) was used for data which were not normally distributed. 
Mann-Whitney U test was used for univariate analysis. Chi-square and Fisher’s Exact test 
were used where appropriate to investigate the association between 2 categorical 
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variables. Statistical significance was set at p<0.05. SPSS version 17.0 was used for data 
analysis. 
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RESULTS 
 
A total of 27 patients with juvenile GPP were identified. The median duration of follow-
up after onset of GPP was 8.8 years (IQR: 4.3, 22.8 years). The median age of patients 
was 16.3 years (IQR: 11.5, 24.9). Female to male ratio was 1.4: 1. Seventy-four percent 
of our patients were Malay, 22.2% Chinese and 3.7% Indian. The median age at onset of 
GPP was 6.5 years (IQR: 2.0, 11.5). Ten patients had prior PV with a median pre-pustular 
duration of 2.7 years (IQR: 1.0, 3.6). A positive family history of psoriasis was present in 
7 (25.9%) patients. Among them, one patient had a maternal aunt with acute GPP. Table 
1 summarizes the clinical characteristics and laboratory results of the different clinical 
variants of GPP seen. Males appeared to have an earlier onset of pustular psoriasis at a 
median age of 5.5 years (IQR: 2.0, 7.5) compared to 8.2 years (IQR: 3.6, 14.0) in females 
but the difference observed was not statistically significant (p= 0.084). Onset of GPP was 
significantly earlier in patients without prior PV at a median age of 5.1 years (IQR: 1.4, 
7.5) versus 12.0 years (IQR: 6.8, 15.2), (p=0.002).  
 
All 21 patients with acute GPP had widespread erythematous plaques with pustules and 
lakes of pus (Fig.1a). The majority of acute GPP were provoked. Triggers identified in 16 
patients (76.1%) included stress (7 patients), upper respiratory tract infection (URTI, 7 
patients), systemic steroid withdrawal (3 patients), pregnancy (3 patients) and vaccination 
(2 patients). Leukocytosis of ≥12 X109/L was documented in 72.2% of 18 patients with 
available results. All 5 patients with APP had characteristic annular/serpiginous lesions 
with erythematous scaly or pustular margins (Fig.2) without fever. However, one patient 
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with extensive APP had leucocytosis (16 X10
9
/L). Stress, URTI and menstruation were 
identified aggravating factors. The only patient with localized variant of GPP had 
extensive well-defined psoriatic plaques overlying flat pustules (Figs. 3a & b). 
Staphylococcus aureus was cultured from a pustule. She was otherwise well and 
responded to a course of cloxacillin and 6 months of acitretin. Table 2 summarizes the 
clinical course, treatment and outcome of all patients with PP. Sixteen patients with acute 
GPP were admitted for a mean duration of 15.5 days (range 1-38 days). Two among them 
developed severe septicaemia but there was no fatality in this study.  
 
Biopsies performed in 19 patients showed characteristics features of pustular psoriasis 
namely spongiform microabscesses of Munro and Kogoj, superficial perivascular 
infiltrate of lymphocytes and some neutrophils, and dilated, tortuous blood vessels in the 
papillary dermis. Typical epidermal changes of psoriasis namely parakeratosis, regular 
acanthosis, hypogranulosis and suprapapillary plate thinning were prominent only in APP 
and L-PPP. Eight out of 20 patients screened have IL36RN mutations; 5 homozygous 
(115+6T>C/ c.115+6T>C), 1 compound heterozygous (c.115+6T>C/p.Ser113Leu) and 2 
heterozygous (c.115+6T>C/negative). One patient without IL36RN variant has CARD14 
mutation (p.Asp176His substitution).  
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SELECTED CASE REPORTS 
 
Patient 1 is a 14-year-old Malay boy who developed pustular lesions at 3-month-old 
after his 1
st
 Diphtheria-Tetanus-Pertussis vaccination. He was hospitalized and treated as 
infected eczema. The 2
nd
 vaccination with only Diphtheria-Tetanus, 2 months later, 
precipitated a severe, biopsy-confirmed GPP requiring hospitalization and oral acitretin. 
Hence, the 3
rd
 dose of vaccination was omitted. His pustules settled after 2 weeks of 
acitretin which was stopped 1 month later when his skin normalized. His skin remained 
clear for 4 years before he was readmitted for another unprovoked GPP which also 
responded to acitretin 1mg/kg body weight (b.w). He was dependent on acitretin and 
relapsed promptly on withdrawal of treatment.  
 
While on maintenance with acitretin 0.5mg/kg b.w, he still had pustular flares every few 
months which were controlled by dose escalation of acitretin. Flares started with fiery red 
erythematous plaques on abdomen, scrotum and right scapular region which became 
pustular (Figs.4a &b) within a day but further spread was halted with increased dose of 
acitretin. Geographic tongue (Fig. 4c) appeared and disappeared with the flares. Most 
flares were spontaneous but possible triggers included URTI, excessive sun exposure, 
post-varicella and emotional stress namely family disharmony and parental separation. 
Highest leukocytosis documented was 50.4 X10
9
/L (neutrophil, 43.3 X 10
9
/L), CRP was 
107.4 mg/L and ESR was 50mm/hr. Other biochemical tests were normal. ASOT was 
positive (400-800 units/mL, normal range: <200 units/mL) during several flares but 
suggestion for tonsillectomy was rejected. Blood cultures during multiple admissions 
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were negative and skin swabs occasionally grew staphylococcus aureus, staphylococcus 
epidermidis or mixed growths of staphylococcus and acinetobacter baumanii. 
 
His skin was clear in between attacks until PV appeared when he was 8- year-old (Fig. 
4d). His PV progressed slowly into localized variant of GPP (Fig. 4e) by 15 months. 
During these 15 months, he had 4 episodes of acute GPP which was controlled by dose 
escalation of acitretin but his localized variant of GPP responded poorly to acitretin. The 
consequent erythrodermic psoriasis with recurrent pustulosis was inadequately controlled 
with methotrexate 10 mg weekly (0.37mg/kg b.w) and subsequent cyclosporine (5mg/kg 
b.w). Addition of a short course of prednisolone was also not beneficial. Repeated offers 
of biologics were rejected by parents. During the last follow-up in March 2015, patient 
was still erythrodermic (Fig. 4f) with pustules on both legs. He has no family history of 
psoriasis and does not carry IL36RN variant. 
 
Patient 6 is a 12-year-old Malay boy who was admitted for severe acute GPP (Fig.1a) 4 
years ago. He had scalp and groin lesions 1 year before GPP supervened. On admission, 
he was moribund with a temperature of 39.8
0
C. He was tachycardic (pulse rate: 
134/minute), tachypnoeic (respiratory rate: 30/minute) with a blood pressure of 107/40 
(normal range: 90-130/60-90). Intravenous meropenem and amikacin were started by the 
pediatric team. Chest radiography revealed perihilar haziness but sputum culture was 
negative. Laboratory tests showed neutrophilia, elevated ASOT (400 units/mL), raised 
ESR and CRP. However, skin and blood cultures were negative. GPP was confirmed by 
skin biopsy. Acitretin was started on day 6 and patient recovered after 38 days in the 
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ward. He had another pustular flare 1 year later when he defaulted follow-up. He endured 
multiple flares triggered by URTIs while on acitretin and only reverted to PV (Fig.1b) 4 
years later. At the time of writing, he was re-admitted for another severe flare (Fig. 1c & 
d) after his GPP slowly deteriorated over the past 4 months in spite of dose escalation of 
acitretin to 1.5mg/kg b.w. His GPP, fever (38.8
0
C), leukocytosis (29.6 X10
9
/L with 
neutrophil, 23.9 X 10
9
/L), elevated CRP (84.3 mg/L) and ESR 28mm/hour normalized 
after 2 days of cyclosporine (5mg/kg bw) and azithromycin. Other biochemical tests were 
normal. Skin and blood culture were negative. He has compound heterozygous Il36RN 
mutation (c.115+6T>C/p.Ser113Leu). 
 
Patient 14 is a 38-year-old Malay lady with PV since 9-year-old. Pregnancy induced 
GPP at the age of 13.5 years. She had suboptimal response to prednisolone but managed 
to deliver a healthy son. For the last 25 years, she is dependent on retinoid (initially 
etretinate, currently acitretin) to control her GPP. No classic PV was noted ever since and 
ill-defined plaques with pustules appeared promptly when acitretin was reduced to below 
0.5mg/kg b.w. Attempts to switch to methotrexate and cyclosporine failed. She wore 
intrauterine contraceptive device for 5 years and used oral contraception in between this 
period. She was not compliant with oral contraception and underwent two induced 
abortions when she got pregnant while on oral retinoids. One failed induced abortion 
fortunately resulted in a healthy daughter. Another unplanned pregnancy at the age 26 
precipitated severe GPP. Poor response to cyclosporine prompted therapeutic abortion 
together with bilateral tubal ligation. She does not carry IL36RN variant. 
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Patient 18 is a 30-year-old Chinese lady who had abnormal pustular nail lesions since 3-
year-old. She received multiple courses of systemic antifungals before psoriasis was 
diagnosed 3 years later. At age 17 years, she developed acute GPP which settled with 
acitretin but promptly relapsed with dose reduction. Attempt to switch to methotrexate 
failed. Even when her disease was quiescent for >6 months while on acitretin, omission 
of therapy triggers pustular flares within 2 weeks. She is depressed by this dependency on 
acitretin which disrupted her plan to start a family. She is also disturbed by the side-
effects of acitretin namely cheilitis and palmoplantar desquamation. She inherited 
CARD14 variant (pAsp176His) from her maternal aunt who also had recurrent GPP. She 
also feared suffering the same fate as her aunt who had severe pregnancy-induced acute 
GPP with consequent cesarean section and bilateral tubal ligation. 
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DISCUSSION 
 
Juvenile GPP is rare, with few studies that included more than 10 cases.
6-9 
Contradictory 
gender preponderance and variable onset-age were documented in these small case series 
(Table 3).
 6-9
 However, female preponderance seen in this study was also observed in our 
patients with adult-onset GPP.
13  
Disease onset is significantly earlier in our patients 
without prior PV, confirming the results of a Japanese study.
14 
Consistent with previous 
studies,
 
the majority of our juvenile GPP (66.6%) were provoked (Table 3) and 
precipitating factors identified were also similar, namely URTI, stress, systemic steroid 
withdrawal, vaccination and pregnancy.
6-9
  URTI is a major trigger for juvenile GPP 
whereas systemic steroid withdrawal is commonly implicated in adult GPP.
5
 Systemic 
steroid was the most common trigger in our adult-onset GPP, accounting for 44.1% of 
102 patients seen in our institution, followed by pregnancy (16.6%) and URTI (15.7%).
7 
In contrast, juvenile acute GPP in our population was mainly triggered by URTI (33.3%) 
and stress (33.3%), with only 3 cases (14.2%) attributable to systemic steroid. This may 
be because children are less likely to be prescribed systemic steroid and are more 
vulnerable to URTI. 
 
Like what we observed in our previous study on adult GPP,
 
once GPP is initiated by 
whatever trigger, psoriasis remains unstable and pustular ﬂares frequently recur on 
exposure to classic triggers and also for unknown reasons.
13
 Only 7 patients had a single 
episode of severe GPP (BSA>30%) and even then, 2 among them are still on acitretin 
because of prompt relapses on dose reduction (Table 2). Topical treatment was effective 
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in only 4 patients with GPP. Acitretin at 1 mg/kg b.w is our treatment of choice for acute 
GPP and it was effective in controlling acute flares in all 16 patients treated. However, at 
the time of writing, 13 patients were still on acitretin (Table 2). We did not observe any 
significant skeletal toxicity or growth retardation in our patients on long-term acitretin.  
 
Cyclosporine, our treatment of choice for pregnancy-induced GPP, was effective in 
patient 17 who had 2 episodes of pregnancy-induced GPP. Cyclosporine also rapidly 
cooled down the inflammation in 3 other patients (Patient 6, 15 and 21) with severe flares 
while on acitretin. However, it was not effective in patient 14 and 20. We did not use 
methotrexate as first-line therapy but attempts to switch therapy of 3 patients of child-
bearing age (Patient 14, 18 and 20) from acitretin to oral methotrexate failed. 
Prednisolone was used for pregnancy-induced GPP in Patient 14 before cyclosporine was 
available but response was inadequate. Although biologics were reported to be useful in 
juvenile GPP,
15-17
 we have no experience in using them because biologics are not 
registered for the treatment of pediatric psoriasis in Malaysia. Recently, we successfully 
induced remission of a severe protracted flare in Patient 20 with a single dose of 
infliximab 5mg/kg b.w after failing to control her GPP with dose escalation of acitretin 
and cyclosporine.  
 
Consistent with previous studies,
6-9
 our patient with localized variant of GPP reverted 
readily to mild PV while patients with APP continued to have recurrent annular lesions. 
However, one patient with extensive APP and associated leukocytosis, finally converted 
to stable PV with adalimumab after failing phototherapy, methotrexate and cyclosporine. 
  
17 
 
APP is known to be a more benign variant of GPP that responds to topical agents
5,7,13,18
 
but severe juvenile APP that failed conventional systemic therapy and conversion into 
acute GPP had been documented.
7,18
   
 
Juvenile GPP are repeatedly reported to be more benign than adult-onset GPP
6-9,15
 
but in our experience, juvenile GPP, particularly the acute von Zumbusch variant, 
is as recalcitrant as adult-onset GPP. Although acitretin and cyclosporine were 
effective in controlling acute flares, relapses were common and occurred promptly on 
withdrawing effective systemic therapy or on exposure to classic triggers such as URTI 
or stress as illustrated with our case reports. The majority of our patients with acute 
GPP (66.6% of 21 cases) had multiple pustular flares and admissions. Unlike 
previous studies whereby the majority of juvenile acute GPP either developed stable 
PV or entered long-term remission without further systemic therapy,
7-8
 the majority 
of our patients required continuous systemic treatment to prevent recurrences 
(Table 2). After a mean follow-up duration of 14.8 years (range: 0.5 to 45 years), 
only 7 patients reverted/converted to PV while 8 persons continue to have recurrent 
pustular flares, three have persistent acropustulosis (Fig. 5), two were lost to follow-
up and one developed erythroderma with pustulosis. Only 3 out of the 17 patients 
whose initial acute GPP were controlled with systemic agents, were successfully 
weaned off treatment. We found that extensive APP can also be very recalcitrant 
after managing Patient 26 whose severe APP and subsequent arthritis 10 years 
later, finally improved with adalimumab.  
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About 20% of GPP patients carry recessive mutations of IL36RN, the gene encoding the 
IL-36 receptor antagonist.
10
 This antagonist counteracts the pro-inflammatory effects of 
IL36-α, β and γ, a group member of IL-1 family cytokines, and prevent the downstream 
activation of NF-κB signaling. Reports of successful treatment of recalcitrant GPP with 
anakinra, an IL-1-receptor antagonist, supports the importance of IL-1 signaling in the 
pathogenesis of GPP.
19-21 
A systematic review of 233 patients with GPP which included 6 
of our IL36RN-positive and 11 of our IL36RN-negative patients in this study, showed 
that homozygous IL36RN mutations define a more severe phenotype characterized by   
i) early onset, ii) low prevalence of PV and iii) high-risk of systemic inflammation 
(defined as fever >38
0
C and leukocytosis >12 X 10
9
/L).
10
 This review also found that 
heterozygous IL36RN mutations increase disease risk. Although disease onset was 
significantly delayed in heterozygous patients, high prevalence of systemic inflammation 
was seen in both groups.  
 
Within this small subset of 20 patients who were screened for IL36RN mutations, we 
observed similar characteristics; i) disease onset was earlier in homozygous patients 
(median age at onset: 3.5 years versus 11.5 years, p=0.031) ii) prior PV was uncommon 
in IL36RN-positive patients (12.5% versus 66.6%,p=0.028), and  iii) 85.7% of patients 
with one or two disease alleles had systemic inflammation compared to 27.3% of 
IL36RN-negative patients (p=0.050). Additionally, our study showed that IL36RN-
positive patients required long-term systemic maintenance therapy. All eight IL36RN-
positive patients, with a mean follow-up duration of 23.5 years (range 3.3 to 45 years), 
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are still dependent on systemic agents to prevent frequent relapses compared to 50% of 
IL36RN-negative patients(p=0.042).  
 
CONCLUSIONS 
 
Juvenile GPP is a chronic recalcitrant disease. Conventional systemic agents namely 
acitretin and cyclosporine are effective in controlling acute flares but relapses are 
common. IL36RN-positive patients have more severe disease.  
 
 
  
  
20 
 
REFERENCES 
 
1. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. 
Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 
2010;162(3):633-636. 
2. Tollefson MM, Crowson CS, McEvoy MT, Kremers HM. Incidence of psoriasis 
in children: a population-based study. J Am Acad Dermatol. 2010;62:979-987 
3. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical 
review of 1262 cases. Ped Dermatol 2001;18:188-198 
4. Fan X, Xiao FL, Yang S, et al. Childhood psoriasis: a study of 277 patients from 
China. Journal of the European Academy of Dermatology and Venereology, 
2007;21: 762–765 
5. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological 
study of 104 cases. Br J Dermatol 1968;15: 144-146.  
6. Zelickson BD, Muller SA. Generalized pustular psoriasis in childhood: report of 
thirteen cases. Am Acad Dermatol 1991; 24: 186–194 
7. Popadic S, Nikolic M. Pustular Psoriasis in Childhood and Adolescence: A 20-
Year Single-Center Experience. Pediatr Dermatol 2014;31:575-579 
8. Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood 
pustular psoriasis treatment in 30 patients. Pediatr Dermatol 1998;27:349–354 
9. de Oliveira ST, Maragno L, Arnone M et al. Generalized pustular psoriasis in 
childhood. Pediatr Dermatol 2010;27:349–354 
  
21 
 
10. Hussain S, Berki D, Choon SE, et al. IL36RN mutations define a severe auto-
inflammatory phenotype of generalized pustular psoriasis. J Allergy Clin 
Immunol 2015;135:1067-1070 
11. Setta-Kaffeti N, Navarini A, Patel V, et al. Rare pathogenic variants in IL36RN 
underlie a spectrum of psoriasis-associated pustular phenotypes.  J Invest  
Dermatol  2013;133:1366-1369 
12. Berki D, Lu L, Choon SE, et al. Activating CARD14 mutations are associated 
with generalized pustular psoriasis but rarely account for familial recurrence in 
psoriasis vulgaris. J Invest Dermatol 2015;135:2964-2970 
13. Choon SE, Lai NM, Mohammad NA et al. Clinical profile, morbidity, and 
outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen 
in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014;53:676-684. 
14. Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in 
Japan: two distinct groups formed by differences in symptoms and genetic 
background. Acta Derm Venereol 1996; 76: 68 –71 
15. Posso-De Los Rios CJ, Pope E, Lara-Corrales I.  A systematic review of systemic 
medications for pustular psoriasis in pediatrics. Pediatr Dermatol 2014; 31:430-
439. 
16. Fialová J, Vojáčková N, Vaňousová D, Hercogová J. Juvenile generalized 
pustular psoriasis treated with etanercept. Dermatol Ther 2014;27:105-108. 
17. Robinson A, Voorhees ASV, Hsu S et al. Treatment of pustular psoriasis: From 
the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 
2012; 67:279-288. 
  
22 
 
18. Liao PB, Rubinson R, Howard R et al. Annular pustular psoriasis—most common 
form of pustular psoriasis in children: report of three cases and review of the 
literature. Pediatr Dermatol 2002;19:19–25 
19. Viguier M, Guigue P, Pages C et al. Successful treatment of generalized pustular 
psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation 
with IL1RN mutations. Ann Intern Med 2010; 153:66–7 
20. Huffmeier U, Watzold M, Mohr J et al. Successful therapy with anakinra in a 
patient with generalized pustular psoriasis carrying IL36RN mutations. Br J 
Dermatol 2014; 170:202–204  
21. Rossi-Semerano L, Piram M, Chiaverini C et al. First clinical description of an 
infant with interleukin-36-receptor antagonist deﬁciency successfully treated with 
anakinra. Pediatrics 2013; 132: e1043–1047 
  
  
23 
 
TABLES 
Table 1.  Characteristics of 27 Malaysians with juvenile generalized pustular psoriasis  
Clinical variants Acute GPP 
 (n=21) 
Sub-acute APP 
 (n=5) 
L-GPP  
(n=1) 
Gender (female/male) 12/9 3 /2 1 female 
Onset age in years 
(median, IQR) 
7.5 (3.5,14.7) 
 
11.5 (6.5,14.0) 5.0  
Fever 17 (80.9%) 0 0 
Geographic tongue 13 (61.9%) 0 0 
Nail involvement 10 (47.6%)  3 (60.0%) 1 (100%) 
Associated arthritis 5 (23.8%) 1 (20.0%) 0 
Leukocytosis 13 (72.2%) of 
18 available) 
1 (20.0%)   0  
Elevated AST/ALT 2 (11.1% of 18 
available) 
0  0  
ASOT  7 (63.6% of 11 
tested) 
1 (20%) 0  
IL36RN variants 7 ( 43.7% of 16 
tested) 
1 (33% of 3 
tested) 
0 
Biopsy performed  14 (66.6%)  4 (80%) 1 (100%) 
 
GPP: generalized pustular psoriasis of von Zumbusch; APP: annular pustular psoriasis; 
L-GPP: localized variant of GPP
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Table 2. Clinical course, treatment and outcome of 27 patients with juvenile generalized pustular psoriasis 
 
Patient 
number 
Current 
age 
(years) 
GPP  
variant 
Incident 
psoriasis 
Age at GPP 
onset 
(years) 
No. of 
pustular 
episode(s) 
Treatment of 
pustular 
flares 
Current 
psoriasis 
Status on last  
follow up 
Post-PP 
Follow-up 
(years) 
1 14.5 Z  Z 0.3 >20 Acitretin Erythroderma Severe on 
acitretin 
14.3 
2 4.5 Z Z 0.8 1 Acitretin LTF Clear 0.7 
3 30.0 Z Z 
 
5.2 >20 Etretinate, 
Acitretin, 
doxycycline 
ACH Mild on acitretin  24.8 
4 15.3 Z Z 6.5 2 Acitretin Z Clear on topical 8.8 
5 13.1 Z PV 7.0 1 Topical PV Mild on topical   6.1 
6 12.6 Z PV 8.5 5 Acitretin 
CyA 
Z Moderate on CyA  4.1 
7 24.8 Z PV 11.5 5 Acitretin Z Mild on episodic 
acitretin  
13.3 
8 24.8 Z ACH 17.0 1 Acitretin ACH Moderate on 
acitretin  
22.8 
9 3.0 Z Z 0.4 1 Topical LTF Clear on topical  0.5 
10 10.0 Z Z 0.5 1 Topical PV Mild on topical 9.5 
11 7.5 Z Z 6.5 1 Acitretin Z Mild on episodic 
acitretin 
1.5 
12 11.5 Z PV 6.5 1 Topical PV Mild on topical  5.0 
13 10.8 Z Z 7.5 5 Acitretin Z Mild on acitretin 3.3 
14 37.8 Z PV 12.5 10 Etretinate, 
acitretin, 
MTX, CyA, 
prednisolone 
Z Mild on acitretin   25.3 
15 24.3 Z PV 15.0 12 Acitretin, 
CyA 
PV Moderate on 
acitretin  
9.3 
16 24.5 Z PV 14.5 2 Acitretin PV Mild on acitretin 10.0 
17 19.2 Z PV 16.0 2 CyA PV Mild on topical   3.2 
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18 30.0 Z ACH 17.0 3 Acitretin, 
MTX 
Z Moderate on 
acitretin  
27.0 
19 47.5 Z ACH 31.0 4 Etretinate 
Acitretin 
ACH Moderate on 
acitretin 
45.0 
20 41.9 Z Z 9.0 7 Acitretin, 
CyA, MTX, 
infliximab 
Z Moderate on 
acitretin 
32.9 
21 44.5 Z Z 2.0 5 Acitretin 
CyA,  
PV Mild on acitretin 42.6 
22 11.8 APP APP 7.5 1 Acitretin APP Mild on topical   4.3 
23 13.0 APP APP 5.5 1 Topical APP Mild on topical 7.5 
24 16.3 APP APP  11.5 1 Topical APP Mild on topical   4.8 
25 24.3 APP PV 16.0 1 Doxycycline APP Mild on topical   8.3 
26 24.9 APP APP 12.0 1 MTX, CyA, 
phototherapy,
adalimumab 
PV Moderate on 
adalimumab 
12.5 
27 11.5 L PV 5.6 1 Acitretin PV Mild on topical   6.0 
  
PV: psoriasis vulgaris, GPP: generalized pustular psoriasis; Z: acute GPP of von Zumbusch; APP: Annular GPP; L: Localized variant 
of GPP; ACH: Acrodermatitis continua of Hallopeau, LTF: lost to follow-up 
 
MTX: methotrexate; CyA: cyclosporine  
Mild: lesion affects < 10% BSA; Moderate: lesion affects 10-30%, Severe: lesion affects > 30% 
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Table 3. Comparison of clinical studies on juvenile pustular psoriasis 
 
 This study 
(Malaysia)  
n = 27 
Popadic 
(Serbia) 
n = 18 
Oliveira 
(Brazil) 
n = 7 
Zelickson 
(USA) 
n = 13 
Juanqin 
(China) 
n = 30 
Male : female 0.68 1.25 0.75 0.86 2.33 
Mean onset-
age  
(year, range) 
7.2 
(3.6 months – 
16 years) 
6.4 
(1.5 months 
–16 years) 
6.0 
(1 month – 
11 years) 
5.2 
(1week – 17 
years) 
7.0 
(2  – 12 
years) 
Prior psoriasis 
vulgaris 
37.0%  38.9% 33.3%  NA 30.0% 
Associated 
arthritis 
22.2%  0 28.5% NA 6.6% 
Triggers 
identified 
66.6%  NA 80% 92% 66% 
Family history 28.5% 5.5% 14.2% 30.7% NA 
Mortality 0 0 1 0 0 
 
NA: not available 
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LEGENDS 
1. Figure 1 Patient 6 with compound heterozygous IL36RN mutations (a) Extensive 
erythema studded with pustules and lakes of pus in 2011 (b) Classic psoriasis 
vulgaris in 2015 (c) Numerous sterile pustules on erythematous base and (d) 
geographic tongue seen in spontaneous relapse in 2016 while on acitretin 
2. Figure 2 Multiple annular and polycyclic erythematous plaques with pustular 
and/or scaly margins characteristic of annular pustular psoriasis 
3. Figure 3. (a)Extensive psoriasis with some glazed deep red non-scaly plaques and 
(b) flat pustule below scaly plaque characteristic of localized variant of 
generalized pustular psoriasis 
4. Figure 4 Shows sequential clinical variants of psoriasis in Patient 1 (a) 
generalized pustular psoriasis characterized by erythematous plaques with sterile 
pustules, (b) geographic tongue, (c) discrete pustules on scrotal skin, (d) classic 
plaque psoriasis (e) localized variant of GPP with pustules within psoriatic 
plaques and (f) erythrodermic psoriasis with pustulosis 
5. Figure 5. Shows persistent acropustulosis inadequately controlled by acitretin in 
Patient 8 
 
 
 
 
 
